
Opinion|Videos|January 1, 2025
Examining Elafibranor as a Treatment Option for PBC
Panelists discuss how elafibranor demonstrated significant efficacy in the ELATIVE trial, which strengthens confidence in its role as a long-term treatment option for patients with primary biliary cholangitis (PBC) who inadequately respond to ursodeoxycholic acid.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Elafibranor received accelerated approval based on findings from the
ELATIVE study. What are the key efficacy insights from this trial? - Elafibranor was also demonstrated to have long-term safety and efficacy at 3 years. How does this durability affect your clinical decision-making?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Cuts MACE Risk in Diabetes With Heart Disease
2
Erica Schwartz Confirmed as CDC Director Amid Public Health Crises
3
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
4
GLP-1s Linked to Fewer Alcohol-Related Hospitalizations
5



































































































